Treatment outcomes and quality of life with palbociclib in patients with advanced breast cancer who also have other medical conditions: a plain language summary of findings from POLARIS

Plain Language SummaryWhat is this summary about?This summary describes an article published in Cancer Medicine medical journal in April 2026. The article reports the results from a study called POLARIS that looked at treatment outcomes and quality of life for patients with advanced breast cancer (ABC) who also had other medical conditions (also known as comorbidities) in routine clinical practice.Patients with hormone receptor-positive/human epidermal growth factor receptor-negative (HR+/HER2-) ABC were included in the study, including those patients with or without comorbidities. The researchers wanted to know if the presence of comorbidities influenced treatment outcomes and quality of life in patients treated with the medicine, palbociclib plus endocrine therapy. Since patients with HR+/HER2- ABC often receive treatment over a long period of time, quality of life is an important outcome measure along with efficacy and safety outcomes.What are the key takeaways?This study showed that, in routine clinical practice, patients with HR+/HER2- ABC who had fewer comorbidities tended to experience a longer time until (or before) their cancer got worse than people with more comorbidities; they also tended to live longer overall than people with more comorbidities.Patients with some blood and lymphatic system disorders tended to live a shorter amount of time before their cancer got worse than those with other medical conditions; they also tended to live a shorter amount of time overall than those with other medical conditions. Presence of comorbidities did not affect patient quality of life during treatment with palbociclib plus endocrine therapy.What were the main conclusions reported by the researchers?Together with previous results from POLARIS, the results show that treatment with palbociclib given in routine clinical practice works well for a broad group of patients with HR+/HER2- ABC, including patients with comorbidities. Although, as expected, patients with more comorbidities had poorer survival outcomes, presence of comorbidities does not appear to affect patients’ quality of life during treatment.Clinical trial number: NCT03280303